-
Posted by
Two Blokes Apr 24 -
Filed in
Stock
-
3 views
KKR & Co. Inc. is set to report Q1 results on May 1, with low expectations but the potential for a positive surprise, especially after a strong last quarter. The $1.2 billion acquisition of Biotage signals KKR's strategic expansion in life sciences, reinforcing confidence in long-term value despite market challenges. Despite a high valuation and recent stock underperformance, KKR's fundamentals remain strong, with robust cash generation, fundraising momentum, and growing assets under management.
